Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANX007 (Vonaprument) Phase 1b in Glaucoma
NCT04188015Phase 1Completed
- Sponsor
- Annexon Biosciences
- Start
- Jul 2018
- Primary completion
- Jun 2019
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vonaprument in primary open-angle glaucoma (POAG) (3 arms), sponsored by Annexon Biosciences. Primary endpoint: Treatment-Emergent Adverse Events at Day 85. Started Jul 2018; status: completed.
02
Drugs
vonaprument
03
Conditions
primary open-angle glaucoma (POAG)
Beyond the preview
Go deeper on NCT04188015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04188015.